TechCN

Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1

ZUG, Switzerland, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor......